Bristol Myers Squibb’s Psoriatic Arthritis Pill Shows Durable Efficacy After Two Years
Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety in active psoriatic arthritis.
Share
Why It Matters
Bristol Myers Squibb's arthritis medicine kept working well for two years. When a medicine stays effective over time, it gives doctors and patients more confidence to use it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.